Cynata Therapeutics Limited (OTCMKTS:CYYNF – Get Free Report)’s stock price fell 27.9% during mid-day trading on Friday . The stock traded as low as $0.14 and last traded at $0.14. 1,111 shares traded hands during mid-day trading, an increase of 789% from the average session volume of 125 shares. The stock had previously closed at $0.19.
Cynata Therapeutics Stock Performance
The business’s 50 day moving average price is $0.14 and its 200-day moving average price is $0.17.
About Cynata Therapeutics
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease.
Recommended Stories
- Five stocks we like better than Cynata Therapeutics
- There Are Different Types of Stock To Invest In
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Should You Invest in Penny Stocks?
- 3 Stocks With High ROE and Market-Beating Growth Potential
- 10 Best Airline Stocks to Buy
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
Receive News & Ratings for Cynata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
